Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
复制标题
度洛西汀 60 毫克每日一次治疗重度抑郁症的功效、安全性和耐受性。
DOI：
--
复制
发表时间：
2005
影响因子：
2.3
通讯作者：
J. Gama
中科院分区：
文献类型：
--
作者：
P. Cowen;A. Ogilvie;J. Gama
背景
重性抑郁症（MDD）是一个严重的公共卫生问题，给患者个人、家庭和整个社会带来负担。最近，双作用抗抑郁药，阻断血清素（5-HT）和去甲肾上腺素（NA）的再摄取，已被开发出来，希望改善抑郁症的治疗结果。度洛沙汀是一种5-HT和NA双重再摄取抑制剂，最近在美国获得许可用于治疗MDD。
目的
本文总结了度洛沙汀的疗效和耐受性数据，特别参考了临床推荐使用的剂量-每日一次60 mg。通过Medline检索和Eli Lilly/Boehringer Ingelheim的出版物数据库识别出与度洛昔单抗60 mg每日一次相关的论文。
结果
随机化、安慰剂对照研究已经证明了度洛昔单抗60 mg每日一次治疗抑郁症的短期和长期疗效。因此，根据主要疗效指标--17项汉密尔顿抑郁量表（HAMD（17）），度洛沙坦60 mg每日一次在减少MDD症状方面上级安慰剂。HAMD（17）和生活质量指标的子因子也有显著改善。此外，度洛沙汀已被证明可显著减轻经常伴随MDD的全身疼痛。最近的一项安慰剂对照研究表明，度洛西汀改善了老年抑郁症患者的认知和抑郁指标。度洛沙汀似乎具有可接受的耐受性。度洛昔单抗最常见的不良事件为恶心、口干和嗜睡。重要的是，度洛沙汀似乎对血压没有临床显著影响。
结论
总之，度洛昔单抗60 mg每日一次可有效治疗核心抑郁症状以及与抑郁症相关的全身疼痛。
BACKGROUND
Major depressive disorders (MDD) present a significant public health problem, in terms of burden for individual sufferers, their families and society as a whole. Recently, dualacting antidepressants, which block both serotonin (5-HT) and noradrenaline (NA) reuptake, have been developed with the hope of improving depression treatment outcomes. Duloxetine is a dual reuptake inhibitor of 5-HT and NA that has recently been licensed in the USA for the treatment of MDD.
OBJECTIVE
This paper summarises efficacy and tolerability data for duloxetine with particular reference to the dose recommended for clinical use -- 60 mg once daily. Papers relating to duloxetine 60 mg once daily were identified through Medline searches and the publication databases at Eli Lilly/Boehringer Ingelheim.
FINDINGS
Randomised, placebo-controlled studies have demonstrated the efficacy of duloxetine 60 mg once daily for the treatment of depression in the short and long term. Thus, duloxetine 60 mg once daily was superior to placebo in reducing once daily was superior to placebo in reducing MDD symptoms according to the primary efficacy MDD symptoms according to the primary efficacy measure -- the 17-item Hamilton Depression Rating Scale (HAMD(17)). Significantly greater improvements in subfactors of HAMD(17) and quality of life measures were also seen. In addition, duloxetine has been shown significantly to reduce the general aches and pains that frequently accompany MDD. A recent placebo-controlled study demonstrated that duloxetine improved cognition and depression measures in depressed elderly patients. Duloxetine appears to have an acceptable tolerance. The most frequently observed adverse events with duloxetine were nausea, dry mouth and somnolence. Importantly, duloxetine did not appear to have a clinically significant effect on blood pressure.
CONCLUSION
In summary, duloxetine 60 mg once daily is effective for the treatment of core depressive symptoms, as well as general aches and pains associated with depression.
DOI：
10.1152/ajpheart.00048.2004
发表时间：
2004-11-01
影响因子：
4.8
作者：
Murray, DB;Gardner, JD;Janicki, JS
通讯作者：
Janicki, JS
DOI：
10.1016/s0021-9258(19)49547-1
发表时间：
1992-08
期刊：
The Journal of biological chemistry
影响因子：
--
作者：
Rafael Fridman;Thomas R. Fuerst;Robert E. Bird;Matti Hoyhtya;M. Oelkuct;Sue Kraus;D. Komarek
通讯作者：
Rafael Fridman;Thomas R. Fuerst;Robert E. Bird;Matti Hoyhtya;M. Oelkuct;Sue Kraus;D. Komarek
人类肿瘤细胞对胶原基质的重塑需要基质金属蛋白酶-2 的激活和细胞表面缔合。
DOI：
--
发表时间：
1998
期刊：
Cancer research.
影响因子：
--
作者：
Deryugina,EI;Bourdon,MA;Reisfeld,RA;Strongin,A
通讯作者：
Strongin,A